Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799643 · ClinicalTrials.gov registry record · Phase 2
Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II
A Phase 2 study, sponsored by Joslin Diabetes Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 638
- Enrollment target
NCT00799643 is a Phase 2 study that has completed, run by Joslin Diabetes Center. The registered enrollment target is 638 participants.
The verdict
NCT00799643, a Phase 2 study, has completed, sponsored by Joslin Diabetes Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 638 participants
- Enrollment target
Study Summary
Growing evidence over recent years supports a potential role for low grade chronic inflammation in the pathogenesis of insulin resistance and type 2 diabetes. In this study we will determine whether salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effective in lowering sugars in patients with type 2 diabetes. The study will determine whether salicylates represent a new pharmacological option for diabetes management. The study is conducted in two stages. Enrollment in the first stage is complete. The primary objective of the first stage was to select a dose of salsalate that is both well-tolerated and demonstrates a trend toward improvement in glycemic control. The primary objective of Stage 2 of the study is to evaluate the effects of salsalate on blood sugar control in diabetes; the tolerability of salsalate use in patients with type 2 diabetes (T2D); and the effects of salsalate on measures of inflammation, the metabolic syndrome, and cardiac risk.
Interventions
- DRUG Salsalate
- DRUG Salsalate Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 638 participants |
| Start Date | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00799643
The ClinicalTrials.gov registry entry for NCT00799643 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 638 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joslin Diabetes Center, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Salsalate is the first listed.
NCT00799643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00799643 about?
NCT00799643 is a clinical study titled "Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II". Growing evidence over recent years supports a potential role for low grade chronic inflammation in the pathogenesis of insulin resistance and type 2 diabetes. In this study we will determine whether salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effec...
What is the current status of trial NCT00799643?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 638 participants. The study started on 2008-11.
What interventions are being tested in trial NCT00799643?
The interventions under investigation include: Salsalate (DRUG), Salsalate Placebo (DRUG).
Who is sponsoring clinical trial NCT00799643?
This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.